^
Association details:
| Biomarker: | FOLR1 expression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | luveltamab tazevibulin (STRO-002) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
741MO - Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion
Published date:
10/16/2023
Excerpt:
Preliminary data indicate that luvelta has a predictable and manageable safety profile with encouraging clinical activity in pts with recurrent/progressive FolRα expressing EEC.
Trial ID:
